Article
Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
The Journal of pharmacology and experimental therapeutics - 1 Sept 2015
Wan Zirui, Wang Guo, Li Tailin, Xu Biaobo, Pei Qi, Peng Yan, Sun Hong, Cheng Lijuan, Zeng Ying, Yang Guoping, Zhu Yuan-Shan
Abstract excerpt
Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor used to lower blood low-density lipoprotein cholesterol, is a substrate of the membrane ABCG2 exporter. ABCG2 variants have been shown to alter rosuvastatin disposition. The objective of this study is to determine the impact of ABCG2 34/421 compound haplotypes on rosuvastatin pharmacokinetics in healthy Chinese volunteer subjects. Eight...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
